Common questions about Ozurdex (FAQ)
Q: How long does the effect of a single Ozurdex implant last?
A: Official studies indicate that the effect of a single implant typically lasts for a period of approximately 6 months. The need for repeat treatment is considered by the prescribing physician when signs of the condition begin to recur, based on the patient's condition.
Q: What happens to the Ozurdex implant in the eye over time?
A: The implant is constructed using a special biodegradable polymer material that is designed to gradually dissolve inside the eye. This design ensures the medicine is released slowly over several months, and the polymer matrix gradually dissolves and is absorbed locally, meaning the device does not require surgical removal.
Q: Is it common to see small floaters after the Ozurdex procedure?
A: Yes, regulatory documents list vitreous opacities as a common side effect reported in clinical trials. These opacities are often what patients perceive as small floaters or specks in their vision shortly after the injection.
Q: Why is it important to check eye pressure after receiving Ozurdex?
A: The active ingredient in the implant, a corticosteroid, is known to cause a common increase in intraocular pressure (IOP), or eye pressure. For this reason, official safety information indicates that regular monitoring of eye pressure is performed following administration to manage this potential effect.
Q: How long after the implant is placed can I resume contact lens use?
A: Official product information does not specify an exact waiting period for contact lens use. Official guidelines indicate that specific instructions regarding contact lenses and when to resume wearing them are provided by the ophthalmologist, often due to the need for specific eye hygiene precautions.
Q: Is the procedure of placing the implant done under general or local anesthesia?
A: Regulatory administration guidelines state that the procedure requires the use of adequate local anesthesia to numb the eye. The administration is performed in a controlled, sterile setting by a qualified eye doctor.
Q: Is Ozurdex used for conditions other than retinal diseases?
A: The medicine is specifically approved for the treatment of certain eye conditions affecting the back of the eye, such as macular edema and noninfectious posterior segment uveitis. Official documents do not describe any approved uses outside of these specific ocular diseases.
Q: What is the difference between Ozurdex and Lucentis/Eylea/Avastin?
A: Ozurdex is a steroid implant that delivers the drug dexamethasone to suppress inflammation. Other medicines, such as Lucentis, Eylea, and Avastin, belong to a different drug class known as anti-VEGF agents, which work by targeting a specific growth factor.
Q: Can Ozurdex be used in both eyes at the same time?
A: Regulatory guidance states that administering the implant to both eyes at the same visit is generally not recommended. If treatment is required for the contralateral eye, official instructions specify that new sterile equipment and a change of the entire sterile field are necessary.
Q: Is the Ozurdex injection painful?
A: The injection procedure requires the use of local anesthesia to minimize discomfort. However, eye pain is listed in official documents as a common side effect that patients may experience in the period immediately following the injection.
Q: Can Ozurdex affect my vision right after the procedure?
A: Yes, official documentation notes that some patients may experience a degree of visual blurring immediately following the procedure. This is a known and temporary effect of the injection.
Q: How likely is it to get a serious infection after the Ozurdex injection?
A: A serious infection of the eye, known as endophthalmitis, is documented as a rare but serious adverse reaction. The procedure requires specific sterile conditions and microbicides to reduce this known risk associated with intravitreal injections.
Q: Can people with high blood pressure use Ozurdex?
A: Systemic conditions like high blood pressure are not listed as an absolute reason to exclude treatment. Official information notes that when treating conditions like diabetic eye problems, managing systemic factors like blood pressure is an important part of overall medical care.
Q: Is there a maximum number of times I can receive Ozurdex injections?
A: Official information does not define a maximum number of injections, as repeat treatment is based on the patient's need. Some regulatory documents advise caution regarding repeated use, noting an association with increases in certain adverse reactions.
Q: Are there any common long-term effects of repeated Ozurdex use?
A: Regulatory documents indicate that the risk of cataract formation is described as a cumulative risk particularly noted with repeated exposure to the corticosteroid. The management of recurring increases in intraocular pressure is also a long-term factor.
Q: Can the Ozurdex implant move or shift inside the eye?
A: Yes, a shift or implant migration into the anterior chamber (the front part of the eye) is listed as a serious adverse reaction. This risk is primarily associated with patients who have a non-intact posterior lens capsule.
Q: What are the restrictions on activity immediately following the injection?
A: Official patient instructions advise that a person is advised not to drive or use machinery until any temporary visual blurring that occurs after the injection has completely resolved. Official product labeling does not specify other general activity restrictions, beyond advising caution until vision has resolved.
Q: Do studies show that Ozurdex is effective for macular edema?
A: Clinical trials supported the medicine's approval for macular edema. The studies documented an improvement in the percentage of patients achieving a measured change in visual acuity and a reduction in retinal swelling compared to control groups.
Q: Why does Ozurdex need to be injected into the eye (vitreous) and not given as a pill?
A: The formulation is designed for localized action directly inside the eye to treat inflammation in the posterior segment. This route results in minimal absorption of the medicine into the body's general circulation, thereby helping to reduce potential systemic side effects.
Q: Is Ozurdex considered a new or a well-established treatment?
A: Ozurdex was initially approved in 2009. It is considered a well-established, specialized intravitreal implant supported by extensive, multi-center clinical trials referenced in official regulatory documents.
Q: Are there special considerations for older patients using Ozurdex?
A: Regulatory guidelines explicitly state that no dose adjustment is required for geriatric patients (aged 65 years and older). The safety profile observed in older adults was similar to that seen in the general adult population.
Q: Does using Ozurdex affect eligibility for future eye surgeries?
A: The development of cataracts is a common and cumulative risk associated with corticosteroid use. This known side effect may eventually lead to a need for future cataract surgery, a possibility addressed in patient counseling information.
Q: What is the typical time frame for the effect of Ozurdex to start working?
A: Clinical trial data for some approved conditions showed that a noticeable difference in visual improvement compared to the control group was often observed beginning at approximately 1 to 2 months following the administration of the implant.
Q: Can a patient drive themselves home after receiving an Ozurdex injection?
A: Official patient information indicates that a patient is advised not to drive or operate complex machinery until any temporary visual blurring that occurs after the injection has fully cleared.
Q: What should I do if my eye pain gets worse the day after the injection?
A: Patient counseling documents stress that patients should immediately contact their treating ophthalmologist if specific symptoms occur, such as worsening eye pain, a red or light-sensitive eye, or a change in vision.
Q: Can Ozurdex be used by pregnant or breastfeeding individuals?
A: Use is generally not recommended during pregnancy or breastfeeding unless the potential benefit is determined to justify the risk. Regulatory guidelines note that a careful review of the known risks, which are associated with the drug's non-systemic delivery, is necessary when considering use in these populations.
Q: How does Ozurdex compare to laser treatment for the same conditions?
A: Ozurdex and laser treatment are both recognized as established treatment options for conditions like Diabetic Macular Edema (DME). The choice between these approaches is based on the specific condition being treated, as assessed by a medical professional.
Q: What is the success rate described in clinical trials for Ozurdex?
A: Regulatory documents do not provide a single 'success rate' figure. Instead, they report on the percentage of patients in clinical trials who achieved a specific, measured improvement in visual acuity, such as a 15-letter gain, compared to a control group.
Q: Does Ozurdex interact with common blood thinners?
A: Systemic drug interactions are not anticipated. However, official documents advise caution when a patient is taking anti-coagulant or anti-platelet agents (blood thinners) due to the documented risk of haemorrhagic adverse events associated with the injection procedure.
Q: What is the likelihood of a complication requiring surgery after the Ozurdex injection?
A: While surgical intervention is uncommon, the risk of sustained increases in eye pressure (IOP) is documented. This condition may require management with eye drops, and rarely, with surgery to resolve the issue.
Q: How do studies address the long-term safety profile of Ozurdex?
A: Long-term safety information primarily focuses on the cumulative risk of side effects linked to repeated exposure to the steroid. The most notable long-term factors are the increased incidence of cataracts and the management of recurring increases in eye pressure.
Q: What is the role of Ozurdex in treating diabetic eye problems?
A: Ozurdex is officially approved to treat adult patients with Diabetic Macular Edema (DME). Its role is to help reduce the swelling and inflammation that contribute to visual impairment in this diabetic eye condition.
Q: Do patients typically feel the implant in their eye after the procedure?
A: Official documents do not specifically address feeling the implant itself. However, the sensations of a foreign body and eye pain are listed as common adverse reactions that may be experienced in the days following the injection.
Q: Can Ozurdex interact with eye drops I am already using?
A: No systemic drug interactions are expected. In cases where the medicine causes an increase in eye pressure, an eye doctor may prescribe other eye drops (IOP-lowering medications) to manage this effect, which would involve the careful administration of multiple ophthalmic products.
Q: What is the weight of the implant inserted during the procedure?
A: The standard dose is one 0.7 mg Ozurdex implant. This weight represents the total amount of the active ingredient (dexamethasone) that is contained within the polymer drug delivery system.
